A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

por | Ene 1, 2022 | Publicaciones - CIMO-01 | 0 Comentarios

Climent, MA; Font, A; Duran, I; Puente, J; Mendez-Vidal, MJ; Saez, MI; Lobera, CS; Arija, JAA; Gonzalez-Del-Alba, A; Sanchez-Hernandez, A; Fita, MJJ; Esteban, E; Alonso-Gordoa, T; Gonzalez, BM; Maroto, P; Lazaro-Quintela, M; Cassinello-Espinosa, J; Perez-Valderrama, B; Garcias, C; Castellano, D – 2022